Product tanker owners are again facing a threat from larger crude carriers cleaning up to load refined cargoes. The latest ...

(Reuters) -Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss that can ...

Analyst cuts Keros rating to Neutral, citing limited near-term catalysts and cautious investor sentiment. $375M capital return announced, but unclear structure and delayed KER-065 updates weigh on ...

Bank of America Securities analyst Jason Zemansky downgraded Keros Therapeutics, Inc. (NASDAQ:KROS) from Buy to Neutral, lowering the price forecast from $32 to $18. Zemansky noted that Keros has ...

Keros plans to reveal the outcome of its strategic review shortly after the Annual Meeting. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

Keros Therapeutics, Inc. has completed its review of strategic alternatives aimed at maximizing stockholder value and has decided to return $375 million of excess capital to its investors.

Keros’ lead product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, with an initial focus on Duchenne muscular dystrophy.

A live audio webcast of the fireside chat presentation will be available at https://event.webcasts.com/starthere.jsp?ei=1723626&tp_key=42d03cc438&tp_special=8 and an archived replay will be accessible ...

Keros will cut 45% of its workforce, leaving 85 employees and saving about $17 million annually. No improvement in PVR or 6MWD was seen; higher pericardial effusions in cibotercept arms vs. placebo.